|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1930b was selected from the N-term region of human EIF2B3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
EIF2B3 catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP. Mutations in each of the five subunits of translation initiation factor eIF2B, including subunit 3, can cause leukoencephalopathy with vanishing white matter. EIF2B3 has also been identified as a cofactor of hepatitis C virus internal ribosome entry site-mediated translation.
van der Knaap, M.S., et al., Ann. Neurol. 51(2):264-270 (2002). Kruger, M., et al., Proc. Natl. Acad. Sci. U.S.A. 97(15):8566-8571 (2000). Gomez, E., et al., Mol. Cell. Biol. 20(11):3965-3976 (2000).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.